510(k) K192209

Citrasate Dry Acid Concentrate, Granuflo Dry Acid Concentrate by Fresenius Medical Care Renal Therapies Group, LLC — Product Code KPO

K192209 is an FDA 510(k) premarket notification submitted by Fresenius Medical Care Renal Therapies Group, LLC for the device "Citrasate Dry Acid Concentrate, Granuflo Dry Acid Concentrate". The FDA issued a decision of Substantially Equivalent on May 8, 2020. The device falls under product code KPO (Dialysate Concentrate For Hemodialysis (Liquid Or Powder)), a Class II device regulated under 21 CFR 876.5820. Fresenius Medical Care Renal Therapies Group, LLC has 52 other 510(k) clearances on record.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
May 8, 2020
Date Received
Aug 14, 2019
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
Dialysate Concentrate For Hemodialysis (Liquid Or Powder)
Device Class
Class II
Regulation Number
876.5820
Review Panel
GU
Submission Type
510(k)

Need the full FDA record for Fresenius Medical Care Renal Therapies Group, LLC? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K192209. Report a data issue: hello@regdatalab.com.